063160.KS
CKD Bio Corp.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 12,350.00
−0.24%Year over year
Reported trailing growth
- Revenue
- -0.6%
- EBITDA
- -46.8%
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- -61.6%
Forward estimates
Based on analyst estimates
- Revenue
- +9.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.9%
- EBITDA
- +103.5%
- EBIT
- -67.1%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026